187269-60-9
常见问题列表
IC50: 88 μM (E-selectin), 20 μM (P-selectin), and 86 μM (L-selectin)
Bimosiamose (TBC-1269) operates by inhibiting neutrophil recruitment to the site of inflammation through blocking the initial rolling phase of recruitment. Bimosiamose (TBC-1269) inhibits cell recruitment and does not possess any cytotoxic effect on neutrophils.
Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved.
Animal Model: | Sprague-Dawley rats (200-225g) with ischemia and reperfusion (I/R) |
Dosage: | 25 mg/kg |
Administration: | Intravenous injection |
Result: | Showed a significant increase in survival compared with controls. |